Journal article
Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients
Atherosclerosis, v 345, pp 33-38
Mar 2022
PMID: 35202959
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Glypican-4 (GPC4) is a cell surface protein, but can be released into circulation under various clinical conditions. The association of circulating GPC4 with the risk of future cardiovascular events or death is unclear. In the present study, we aimed to investigate the association between serum GPC4 and major adverse cardiovascular events (MACE), vascular mortality, and all-cause mortality in a prospective cohort study.
Our study included 760 patients undergoing coronary angiography. During a mean follow up period of 6.3 years, the incidence of MACE, vascular mortality, and all-cause mortality was recorded. Serum GPC4 levels were determined using an enzyme-linked immunosorbent assay.
Serum GPC4 was highly significantly associated with increased age, body mass index, brain natriuretic peptide, and oxidized low density lipoprotein, as well as with decreased estimated glomerular filtration rate. During the follow-up period, 145 patients died, including 67 vascular deaths. MACE occurred in 137 patients. Serum GPC4 was significantly associated with MACE, vascular mortality, and all-cause mortality independently of traditional cardiovascular risk factors, with adjusted hazard ratios (HR) and 95% confidence intervals for one standard deviation change of serum GPC4 of 1.32 [1.10–1.58], 1.38 [1.06–1.78], and 1.53 [1.29–1.82], respectively. The best cut-off value for serum GPC4 for predicting MACE, vascular mortality, and all-cause mortality was 7.24 ng/ml for all three endpoints. Respective adjusted HRs were 1.61 [1.07–2.43], 2.85 [1.62–5.01], and 2.92 [2.00–4.27].
Our study indicates that elevated serum GPC4 levels are significantly associated with an increased risk of MACE, vascular mortality, and all-cause mortality.
[Display omitted]
•Serum levels of GPC4 are associated with traits linked to insulin resistance or obesity.•Serum levels of GPC4 predict future major adverse cardiovascular events and mortality.•Serum levels of GPC4 predict risk independently of traditional cardiovascular risk factors.•Serum levels of GPC4 add additional predictive value to a basic model for mortality.
Metrics
Details
- Title
- Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients
- Creators
- Axel Muendlein - Vorarlberg Institute for Vascular Investigation and TreatmentEva Maria Brandtner - Vorarlberg Institute for Vascular Investigation and TreatmentAndreas Leiherer - Vorarlberg Institute for Vascular Investigation and Treatment VIVIT, Feldkirch, AustriaKathrin Geiger - Vorarlberg Institute for Vascular Investigation and Treatment VIVIT, Feldkirch, AustriaChristine Heinzle - Vorarlberg Institute for Vascular Investigation and TreatmentStella Gaenger - Vorarlberg Institute for Vascular Investigation and TreatmentPeter Fraunberger - Medical Central Laboratories, Feldkirch, AustriaArthur Mader - Vorarlberg Institute for Vascular Investigation and TreatmentChristoph H. Saely - Vorarlberg Institute for Vascular Investigation and TreatmentHeinz Drexel - Drexel University, College of Medicine
- Publication Details
- Atherosclerosis, v 345, pp 33-38
- Publisher
- Elsevier B.V
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:000792680700005
- Scopus ID
- 2-s2.0-85126145989
- Other Identifier
- 991021861285204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Peripheral Vascular Disease